<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34935570</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms.</ArticleTitle>
        <Pagination>
          <StartPage>11</StartPage>
          <EndPage>21</EndPage>
          <MedlinePgn>11-21</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2021.2014555</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Clinical manifestations of hypereosinophilic syndrome (HES) are diverse. This study aimed to summarise these clinical characteristics with asthma-like onset as the first symptom, and compare these characteristics and treatment strategies between idiopathic and parasitic HES.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We retrospectively analysed 36 HES patients with asthma-like symptoms as the first episode, between January 2013 and October 2019. Data of patients with HES of an unknown cause (idiopathic HES) and parasitic infection (parasite HES) were analysed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The idiopathic and parasite HES groups included 16 and 20 patients, respectively, with more males in the parasite HES group (<i>p</i> &lt; .05). Wheezing and dry rales was the most common symptom and signs, with no significant differences in symptoms and signs between the groups. The most often misdiagnosed disease was bronchial asthma. The peripheral blood eosinophil count was significantly increased compared with normal counts in both groups (<i>p</i> &gt; .05). Abnormal pulmonary function is mainly manifested as obstructive ventilatory disorder and mixed ventilatory disorder. Chest computed tomography showed extensive ground-glass exudation, patches, consolidation, nodules, and pleural effusion. Histopathological examination showed eosinophilic infiltration without vasculitis or granuloma. Glucocorticoids had a significant therapeutic effect, and the parasite HES group required combined deworming drugs. The duration of corticosteroids therapy in the idiopathic HES group was significantly longer than that in the parasite HES group (<i>p</i> &lt; .05). The overall prognosis was good, and 81.25% of the patients were clinically cured in the parasite HES group; however, relapse occurred easily in the idiopathic HES group.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Asthma-like symptoms, obstructive ventilatory disorder or positive bronchial dilation test, and poor response to inhaled corticosteroids are not necessarily indicative of refractory asthma; HES should be considered. The clinical characteristics of HES of different aetiologies are similar. Systemic corticosteroid therapy is preferred for idiopathic and parasitic infections. Idiopathic HES is treated with prolonged corticosteroids and relapses easily.Key MessagesAsthma-like symptoms, obstructive ventilatory disorder or positive bronchial dilation tests, and poor responses to inhaled corticosteroids are not necessarily indicative of refractory asthma, and hypereosinophilic syndrome should be considered.The clinical characteristics of hypereosinophilic syndrome of different aetiologies are similar, and systemic glucocorticoid therapy is preferred for both idiopathic and parasitic infections.Idiopathic hypereosinophilic syndrome is treated with prolonged corticosteroids and relapses easily.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaofeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Zuyou</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Jiehua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Suke</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jianquan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, The Eighth Affiliated Hospital, Sun Yat Sen University, Shenzhen, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017681" MajorTopicYN="Y">Hypereosinophilic Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Eosinophils</Keyword>
        <Keyword MajorTopicYN="Y">glucocorticoid</Keyword>
        <Keyword MajorTopicYN="Y">idiopathic</Keyword>
        <Keyword MajorTopicYN="Y">parasitic infection</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>12</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34935570</ArticleId>
        <ArticleId IdType="pmc">PMC8725856</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2021.2014555</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Valent P, Klion AD, Horny HP, et al. . 
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4091810</ArticleId>
            <ArticleId IdType="pubmed">22460074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunagawa K, Nishio H, Kinukawa N, et al. . 
An autopsy case of disseminated strongyloidiasis combined with cytomegalovirus infection. Jpn J Infect Dis. 2011;64(2):150–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21519131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mocumbi AO, Goncalves C, Damasceno A, et al. . 
Active schistosomiasis, severe hypereosinophilia and rapid progression of chronic endomyocardial fibrosis. Cardiovasc J Afr. 2016;27(5):e4–e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5378935</ArticleId>
            <ArticleId IdType="pubmed">27805245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolnough K, Wardlaw AJ.. 
Eosinophilia in pulmonary disorders. Immunol Allergy Clin North Am. 2015;35(3):477–492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26209896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima Álvarez J, Peña Griñán N, Simón Pilo I.. 
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. Arch Bronconeumol. 2016;52(10):538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27185511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krenke R, Nasilowski J, Korczynski P, et al. . 
Incidence and aetiology of eosinophilic pleural effusion. Eur Resp J. 2009;34(5):1111–1117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19386682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papakosta D, Manika K, Kyriazis G, et al. . 
Bronchoalveolar lavage fluid eosinophils are correlated to natural killer cells in eosinophilic pneumonias. Respiration. 2009;78(2):177–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19246876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spry CJ, Davies J, Tai PC, et al. . 
Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52(205):1–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6878618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan WA, Santhanakrishnan K.. 
Hypereosinophilic syndrome secondary to strongyloides infection: a case of recurrent asthma exacerbations. BMJ Case Rep. 2013;2013(1):bcr2013009587–bcr2013009587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3761444</ArticleId>
            <ArticleId IdType="pubmed">23964035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karnak D, Kayacan O, Beder S, et al. . 
Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. CMAJ. 2003;168:172–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC140426</ArticleId>
            <ArticleId IdType="pubmed">12538545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim KS, Ko J, Lee SS, Shin B, et al. . 
A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome. Allergy Asthma Immunol Res. 2014;6(1):98–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3881409</ArticleId>
            <ArticleId IdType="pubmed">24404401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Zhang J, Zhang X, et al. . 
Cough in hypereosinophilic syndrome: case report and literature review. BMC Pulmon Med. 2020;20:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7158094</ArticleId>
            <ArticleId IdType="pubmed">32293378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu P, Chen Y, Zhang H, et al. . 
Idiopathic hypereosinophilic syndrome presenting with multiple organ damage: a case report. Medicine. 2019;98(10):e14532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6417528</ArticleId>
            <ArticleId IdType="pubmed">30855439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang KJ, Heo SH, Chang DI.. 
Multiple microembolic brain infarctions in Clonorchis sinensis infestation. J Neurol Sci. 2012;319(1–2):133–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22656183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dulohery MM, Patel RR, Schneider F, et al. . 
Lung involvement in hypereosinophilic syndromes. Respir Med. 2011;105(1):114–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21036585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Håkansson KEJ, Rasmussen LJH, Godtfredsen NS, et al. . 
The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma – a retrospective cohort study. Respir Res. 2019;20(1):258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6858677</ArticleId>
            <ArticleId IdType="pubmed">31730462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lababidi HM, AlSowayigh OM, BinHowemel SF, et al. . 
Refractory asthma phenotyping based on immunoglobulin E levels and eosinophilic counts: a real life study. Respir Med. 2019;158:55–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31605922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijnant SRA, Lahousse L, De Buyzere ML, et al. . . Prevalence of asthma and COPD AND blood eosinophil count in a Middle-aged belgian population. JCM. 2019;8(8):1122.doi:10.3390/jcm8081122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8081122</ArticleId>
            <ArticleId IdType="pmc">PMC6723474</ArticleId>
            <ArticleId IdType="pubmed">31357728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JG, Mahmud SA, Thompson JA, et al. . 
The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006;107(2):558–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1895611</ArticleId>
            <ArticleId IdType="pubmed">16166591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moosbauer C, Morgenstern E, Cuvelier SL, et al. . 
Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood. 2007;109(3):995–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17003379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cugno M, Marzano AV, Lorini M, et al. . 
Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLOS One. 2014;9(11):e111862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4222944</ArticleId>
            <ArticleId IdType="pubmed">25375118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D, Xu L, Lin D, et al. . 
Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome. Respir Med Case Rep. 2018;25:213–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6143698</ArticleId>
            <ArticleId IdType="pubmed">30237972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todd S, Hemmaway C, Nagy Z.. 
Catastrophic thrombosis in idiopathic hypereosinophilic syndrome. Br J Haematol. 2014;165(4):425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24456103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen TS, Xing LH, Wang SL, et al. . 
Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome. Blood Coagul Fibrinolysis. 2016;27(7):831–834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26780165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dispenza MC, Bochner BS.. 
Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes. Curr Hematol Malig Rep. 2018;13(3):191–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6029712</ArticleId>
            <ArticleId IdType="pubmed">29680938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stella S, Massimino M, Manzella L, et al. . 
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes. IJMS. 2021;22(2):486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7825323</ArticleId>
            <ArticleId IdType="pubmed">33418988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shomali W, Gotlib J.. 
World health organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(10):1149–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31423623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogbogu PU, Bochner BS, Butterfield JH, et al. . 
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319–1325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2829669</ArticleId>
            <ArticleId IdType="pubmed">19910029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helbig G.
Imatinib for the treatment of hypereosinophilic syndromes. Expert Rev Clin Immunol. 2018;14(2):163–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29303368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hana CK, Caldera H.. 
Hypereosinophilic syndrome, multiorgan involvement and response to imatinib. Cureus. 2020;12(6):e8493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7343300</ArticleId>
            <ArticleId IdType="pubmed">32656011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstovsek S, Tefferi A, Kantarjian H, et al. . 
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):368–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822510</ArticleId>
            <ArticleId IdType="pubmed">19118067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin JJ, Butterfield JH, Weiler CR.. 
Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2015;3(6):920–925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26342744</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
